Stefan D Baral1, Susanne Strömdahl, Chris Beyrer. 1. Center for Public Health and Human Rights, Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA. sbaral@jhsph.edu
Abstract
PURPOSE OF REVIEW: Oral preexposure prophylaxis (PrEP) has shown HIV preventive efficacy for several key populations at risk for HIV infection including MSM and heterosexual men and women in HIV serodiscordant relationships. An efficacy trial of daily oral tenofovir among people who inject drugs (IDU) is underway in Thailand. RECENT FINDINGS: Although efficacy data is pending, there is emerging biological and public health plausibility data suggesting the utility of PrEP as an effective component of combination HIV prevention for IDU. Drawing from studies characterizing adherence to antiretroviral therapy for IDU, there are a range of scientific and operational considerations for the potential use of PrEP for IDU. We review here the available literature on the potential use of PrEP for IDU, barriers to uptake and adherence, and potential implementation science questions, which could address, and potently increase, the effectiveness of this intervention. SUMMARY: IDU remain the most underserved population in the HIV response worldwide, and have a marked gap in prevention services, making PrEP a potentially promising addition to the prevention toolkit for people who use drugs and, for those already living with HIV infection, for their spouses and other sexual partners.
PURPOSE OF REVIEW: Oral preexposure prophylaxis (PrEP) has shown HIV preventive efficacy for several key populations at risk for HIV infection including MSM and heterosexual men and women in HIV serodiscordant relationships. An efficacy trial of daily oral tenofovir among people who inject drugs (IDU) is underway in Thailand. RECENT FINDINGS: Although efficacy data is pending, there is emerging biological and public health plausibility data suggesting the utility of PrEP as an effective component of combination HIV prevention for IDU. Drawing from studies characterizing adherence to antiretroviral therapy for IDU, there are a range of scientific and operational considerations for the potential use of PrEP for IDU. We review here the available literature on the potential use of PrEP for IDU, barriers to uptake and adherence, and potential implementation science questions, which could address, and potently increase, the effectiveness of this intervention. SUMMARY: IDU remain the most underserved population in the HIV response worldwide, and have a marked gap in prevention services, making PrEP a potentially promising addition to the prevention toolkit for people who use drugs and, for those already living with HIV infection, for their spouses and other sexual partners.
Authors: Suphak Vanichseni; Jordan W Tappero; Punnee Pitisuttithum; Dwip Kitayaporn; Timothy D Mastro; Eiam Vimutisunthorn; Frits van Griensvan; William L Heyward; Donald P Francis; Kachit Choopanya Journal: AIDS Date: 2004-01-23 Impact factor: 4.177
Authors: Alan E Greenberg; Jordan Tappero; Kachit Choopanya; Frits van Griensven; Mike Martin; Suphak Vanichseni; Scott Santibanez; Valerie Molotilov; Shannon Hader; Laura N Broyles Journal: J Urban Health Date: 2005-09 Impact factor: 3.671
Authors: Pravan Suntharasamai; Michael Martin; Suphak Vanichseni; Frits van Griensven; Philip A Mock; Punnee Pitisuttithum; Jordan W Tappero; Udomsak Sangkum; Dwip Kitayaporn; Marc Gurwith; Kachit Choopanya Journal: Addiction Date: 2009-02 Impact factor: 6.526
Authors: S Mayhew; M Collumbien; A Qureshi; L Platt; N Rafiq; A Faisel; N Lalji; S Hawkes Journal: Sex Transm Infect Date: 2009-04 Impact factor: 3.519
Authors: Angela R Bazzi; Dea L Biancarelli; Ellen Childs; Mari-Lynn Drainoni; Alberto Edeza; Peter Salhaney; Matthew J Mimiaga; Katie B Biello Journal: AIDS Patient Care STDS Date: 2018-10-11 Impact factor: 5.078
Authors: E Jennifer Edelman; Brent A Moore; Sarah K Calabrese; Gail Berkenblit; Chinazo Cunningham; Viraj Patel; Karran Phillips; Jeanette M Tetrault; Minesh Shah; David A Fiellin; Oni Blackstock Journal: AIDS Behav Date: 2017-04
Authors: Katherine H A Footer; Sahnah Lim; Christine Tagliaferri Rael; George J Greene; Alex Carballa-Diéguez; Rebecca Giguere; Michelle Martinez; Walter Bockting; Richard D'Aquila; Susan G Sherman Journal: AIDS Care Date: 2019-03-01
Authors: Hyman M Scott; Matthew Spinelli; Eric Vittinghoff; Alicia Morehead-Gee; Anne Hirozawa; Catherine James; Hali Hammer; Albert Liu; Monica Gandhi; Susan Buchbinder Journal: AIDS Date: 2019-11-15 Impact factor: 4.177
Authors: Katie B Biello; Matthew J Mimiaga; Pablo K Valente; Nimish Saxena; Angela R Bazzi Journal: Curr HIV/AIDS Rep Date: 2021-04-27 Impact factor: 5.495
Authors: Audrey Pettifor; Nadia L Nguyen; Connie Celum; Frances M Cowan; Vivian Go; Lisa Hightow-Weidman Journal: J Int AIDS Soc Date: 2015-02-26 Impact factor: 5.396
Authors: Daniel J Escudero; Mark N Lurie; Thomas Kerr; Chanelle J Howe; Brandon D L Marshall Journal: J Int AIDS Soc Date: 2014-03-27 Impact factor: 5.396